Note: This document contains side effect information about lanreotide. Some dosage forms listed on this page may not apply to the brand name Somatuline Depot.

Summary

Common side effects of Somatuline Depot include: diarrhea. Other side effects include: cholelithiasis, hypertension, and sinus bradycardia. Continue reading for a comprehensive list of adverse effects.

Applies to lanreotide: parenteral injection.

Side effects include:

Diarrhea, abdominal pain, nausea, constipation, flatulence, vomiting, cholelithiasis, injection site reactions, arthralgia, headache, musculoskeletal pain, hyperglycemia, hypertension, dizziness, and muscle spasm.

For Healthcare Professionals

Applies to lanreotide: subcutaneous solution.

General

The most common adverse events were gastrointestinal disorders, cholelithiasis, and injection site reactions.^[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (up to 65%), abdominal pain (34%), vomiting (19%), flatulence (14%), nausea (11%), loose stools

Common (1% to 10%): Constipation, flatulence, abdominal distension, abdominal discomfort, dyspepsia

Uncommon (0.1% to 1%): Pancreatitis, feces discolored

Frequency not reported: Steatorrhea^[Ref]

In one of the studies, diarrhea, abdominal pain, and flatulence increased as the dose increased.^[Ref]

Hepatic

Very common (10% or more): Cholelithiasis (27%), bladder sludge (20%), new cholelithiasis

Common (1% to 10%): ALT increased, AST abnormal, ALT abnormal, blood bilirubin increased, biliary dilatation

Uncommon (0.1% to 1%): AST increased, blood alkaline phosphatase increased, blood bilirubin abnormal

Frequency not reported: Cholecystitis

Postmarketing reports: Steatorrhea, pancreatitis^[Ref]

Cardiovascular

Very common (10% or more): Bradycardia (18%), hypertension (14%)

Common (1% to 10%): Sinus bradycardia

Uncommon (0.1% to 1%): Other cardiac adverse drug reactions^[Ref]

Local

Very common (10% or more): Application site disorder (injection site mass/pain/reaction/inflammation/ nodule/pruritus, 30%)

Postmarketing reports: Persisting induration, injection site abscess^[Ref]

Metabolic

Very common (10% or more): Dysglycemia (hypoglycemia, hyperglycemia, diabetes, 14%), weight decrease (11%)

Common (1% to 10%): Blood glucose increased, glycosylated hemoglobin increased

Uncommon (0.1% to 1%): Blood sodium decreased, diabetes mellitus aggravated^[Ref]

Hematologic

Very common (10% or more): Anemia (14%)^[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (19%), arthralgia (11%)^[Ref]

Nervous system

Very common (10% or more): Headache (16%)

Common (1% to 10%): Dizziness

Postmarketing reports: Dysautonomia^[Ref]

Respiratory

Common (1% to 10%): Dyspnea^[Ref]

Psychiatric

Common (1% to 10%): Depression

Uncommon (0.1% to 1%): Insomnia^[Ref]

Other

Common (1% to 10%): Fatigue

Uncommon (0.1% to 1%): Hot flush, asthenia

Postmarketing reports: Malaise^[Ref]

Immunologic

Common (1% to 10%): Anti-lanreotide (the active ingredient contained in Somatuline Depot) antibodies^[Ref]

Hypersensitivity

Frequency not reported: Allergic reactions (including angioedema, anaphylaxis, and hypersensitivity)^[Ref]

Dermatologic

Common (1% to 10%): Alopecia, hypotrichosis^[Ref]

Endocrine

Rare (less than 0.1%): Clinical hypothyroidism

Frequency not reported: Slight decreases in thyroid function^[Ref]